Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RIDE versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RIDE versus METAHYDRIN.
HYDRO-RIDE vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Terminal half-life 4-6 hours (prolonged in renal impairment).
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic